Results 11 to 20 of about 36,129 (239)
Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center ...
Eun Hye Oh +9 more
doaj +1 more source
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness.
Michael Benzaquen +7 more
doaj +1 more source
Adalimumab, an entirely human monoclonal antibody, specifically blocks the cell-surface receptor relationship of tumor necrosis factor-alpha (TNF-α) with p55 and p75 TNF-α, thereby suppressing the biological activity of TNF-α. It received FDA approval in 2008 for the treatment of moderate to severe psoriasis that does not respond to conventional ...
openaire +3 more sources
Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG +5 more
doaj +1 more source
This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis ...
Xiaoliang Ding +5 more
doaj +1 more source
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligible ...
Grégoire Cormier +20 more
doaj +1 more source
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki +13 more
doaj +1 more source
Background: Tumor necrosis factor (TNF) inhibitors have been used in the treatment of cardiac sarcoidosis, infliximab being the most commonly used.
Jaleel Jerry G. Sweis +14 more
doaj +1 more source
Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
Background Adalimumab in combination with other disease-modifying antirheumatic drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis.
DA Al-Julandani +6 more
doaj +1 more source
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj +1 more source

